Advances in medical technology are transforming the lives of people worldwide. For those living with Parkinson’s disease, like my father who passed away due to the condition, these developments bring immense hope for improved quality of life. Recently approved devices offer more economical treatment options and enhanced patient outcomes.
The U.S. Food and Drug Administration (FDA) has cleared OrthoNovis Inc.’s wrist fracture system, allowing it to compete in the US orthopedic market. This 510(k) clearance enables locking wrist plates designed for fixation of certain fractures, fusions, or osteotomies in the distal radius.
Medtronic plc has also received FDA approval for its BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI). aDBS uses real-time brain activity to personalize therapy for Parkinson’s patients. This feature automatically adjusts treatment based on brain signals, reducing manual adjustments required by patients.
BrainSense EI helps reduce patient time in clinic settings by conducting accurate and precise initial programming 85% faster than traditional methods. With these advancements, clinicians can provide enhanced symptom control for patients with debilitating neurological disorders.
While there is no cure for Parkinson’s, deep brain stimulation (DBS) has been a game-changer for over 30 years, transforming lives of those affected by the condition. The approval of BrainSense technology further empowers clinicians to deliver personalized therapy to patients in need.
Source: https://www.todaysmedicaldevelopments.com/news/medtronic-earns-approval-for-adaptive-deep-brain-stimulation-system-orthonovis-gets-clearance-to-market-wrist-fracture-system